EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gly-β-MCA is a potent anti-cholestasis agent against “human-like” hydrophobic bile acid-induced biliary injury in mice

Mohammad Nazmul Hasan, Huaiwen Wang, Wenyi Luo, Yung Dai Clayton, Lijie Gu, Yanhong Du, Sirish K Palle, Jianglei Chen, Tiangang Li

Journal of Lipid Research · 2024

DOI: 10.1016/j.jlr.2024.100649 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Lipid Research, 2024. Verfasst von Mohammad Nazmul Hasan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biochemistry and Physiology, Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Hauptthemen laut MEDLINE: Cholestasis, Bile Acids and Salts, Hydrophobic and Hydrophilic Interactions. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NCATS NIH HHS, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cholestasis is a chronic liver disease with limited therapeutic options. Hydrophobic bile acid-induced hepatobiliary injury is a major pathological driver of cholestasis progression. This study investigates the anti-cholestasis efficacy and mechanisms of action of glycine-conjugated β-muricholic acid (Gly-β-MCA). We use female Cyp2c70 KO mice, a rodent cholestasis model that does not produce endogenous muricholic acid (MCA) and exhibits a "human-like" hydrophobic bile acid pool and female-dominant progressive hepatobiliary injury and portal fibrosis. The efficacy of Gly-β-MCA and ursodeoxycholic acid (UDCA), the first line drug for cholestasis, on cholangiopathy and portal fibrosis are compared. At a clinically relevant dose, Gly-β-MCA shows comparable efficacy as UDCA in reducing serum transaminase, portal inflammation and ductular reaction, and better efficacy than UDCA against portal fibrosis. Unlike endogenous bile acids, orally administered Gly-β-MCA is absorbed at low efficiency in the gut and enters the enterohepatic circulation mainly after microbiome-mediated deconjugation, which leads to taurine-conjugated MCA enrichment in bile that alters enterohepatic bile acid pool composition and reduces bile acid pool hydrophobicity. Gly-β-MCA also promotes fecal excretion of endogenous hydrophobic bile acids and decreases total bile acid pool size, while UDCA treatment does not alter total bile acid pool. Furthermore, Gly-β-MCA treatment leads to gut unconjugated MCA enrichment and reduces gut hydrophobic lithocholic acid (LCA) exposure. In contrast, UDCA treatment drives a marked increase of LCA flux through the large intestine. In conclusion, Gly-β-MCA is a potent anti-cholestasis agent with potential clinical application in treating human cholestasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CholestasisBile Acids and SaltsHydrophobic and Hydrophilic InteractionsAnimalsMiceFemaleGlycineMice, KnockoutHumansUrsodeoxycholic AcidCholic AcidsCytochrome P-450 Enzyme System

Stichwörter der Autor:innen

CYP7A1FXRbile acidcholangiopathydrug therapylivernuclear receptor

Substanzen

Bile Acids and Saltsmuricholic acidGlycineUrsodeoxycholic Acidcytochrome P-450 2C70, mouseCholic AcidsCytochrome P-450 Enzyme System

Autor:innen und Institutionen

  • Department of Biochemistry and Physiology, Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Laboratory for Molecular Biology and Cytometry Research, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Department of Pathology, Yale University, New Haven, CT, USA.
  • Department of Pediatrics, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA.
  • Department of Biochemistry and Physiology, Harold Hamm Diabetes Center, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA. Electronic address: tiangang-li@ouhsc.edu.

Förderung

  • NIDDK NIH HHS
  • NCATS NIH HHS
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases

Zitieren

APA

Hasan, M. N., Wang, H., Luo, W., Clayton, Y. D., Gu, L., Du, Y., Palle, S. K., Chen, J., & Li, T. (2024). Gly-β-MCA is a potent anti-cholestasis agent against “human-like” hydrophobic bile acid-induced biliary injury in mice. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2024.100649

Vancouver

Hasan MN, Wang H, Luo W, Clayton YD, Gu L, Du Y, et al. Gly-β-MCA is a potent anti-cholestasis agent against “human-like” hydrophobic bile acid-induced biliary injury in mice. Journal of Lipid Research. 2024. doi:10.1016/j.jlr.2024.100649

BibTeX
@article{Hasan2024,
  author = {Hasan, Mohammad Nazmul and Wang, Huaiwen and Luo, Wenyi and Clayton, Yung Dai and Gu, Lijie and Du, Yanhong and Palle, Sirish K and Chen, Jianglei and Li, Tiangang},
  title = {Gly-β-MCA is a potent anti-cholestasis agent against “human-like” hydrophobic bile acid-induced biliary injury in mice},
  journal = {Journal of Lipid Research},
  year = {2024},
  doi = {10.1016/j.jlr.2024.100649}
}
Kostenlos starten →